AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01924780 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stimulation 10 minutes
Description: NEMOS transvagal stimuli 10 minutes
Study NCT01924780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEMOS transvagal stimulation 60 minutes
Description: NEMOS Device stimulation in 60 minutes
Study NCT01924780 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NEMOS transvagal stimulation 60 minutes
Description: NEMOS Device stimulation in 60 minutes
Study NCT01924780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEMOS Device sham stimulation 10 minutes
Study NCT02509767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous depot medroxyprogesterone acetate
Description: Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
Study NCT02509767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous depot medroxyprogesterone acetate
Description: Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
Study NCT03986424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akatinol Memantine 20 mg
Description: Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
Study NCT03986424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Akatinol Memantine 10 mg
Description: Akatinol Memantine 10 mg to be taken orally, twice daily
Study NCT00670020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supplemental perioperative oxygen
Description: increased perioperative oxygen verses non-interventional oxygen
Study NCT01533519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y
Description: Intranasal administration will be administered with a nasal drug delivery device.
Study NCT01918163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate pills
Study NCT01943799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
Study NCT01943799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAV Regimen
Description: Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
Study NCT00687388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selective alpha 1-blockers
Description: Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
Study NCT00687388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: 200mg daily for 8 weeks
Study NCT00687388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-blocker and NSAID
Description: amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
Study NCT02884544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100
Description: Treatment
Study NCT00568958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo naltrexone
Description: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
Study NCT04037436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and Balance Training & Nutrition Education
Description: Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
Study NCT04037436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
Study NCT01051986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saphenous vein composite grafting
Description: use saphenous vein as a composite graft connected to the left internal thoracic artery
Study NCT01051986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right internal thoracic artery composite grafting
Description: right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
Study NCT00556218 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tibetan Meditation Program
Description: 12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
Study NCT00556218 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Meditation
Description: No meditation; usual care.
Study NCT03179514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.
Study NCT03179514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.
Study NCT03179514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipid Regulating Drugs
Description: Mainly including statins
Study NCT03179514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins
Study NCT03179514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Coronary Vasodilator
Description: Mainly including nitrates
Study NCT03179514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates
Study NCT03179514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gualou Xiebai Banxia Decoction & Danshen Decoction
Description: Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Study NCT01717664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-104
Description: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
Study NCT01151046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
Study NCT01151046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
Study NCT01151046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane (25 mg) administered orally once per day
Study NCT01151046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Exemestane (25 mg) administered orally once per day
Study NCT00849121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
Study NCT00849121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
Study NCT00127530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine-SR
Description: Tablets, 10 mg, twice daily, 14 weeks
Study NCT00127530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill, twice a day (b.i.d.)
Study NCT04872335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong's Mobilization
Description: Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
Study NCT04872335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gradually Graded Exercise Therapy
Description: The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug.
Study NCT02685488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Ultrasound Power
Description: Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
Study NCT02685488 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Ultrasound Sham
Description: Transcranial ultrasound will be used without power for a sham condition.
Study NCT00866866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: 600 mg PO BID
Study NCT00866866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab PO BID
Study NCT02980718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive olfactory training
Study NCT02980718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ordinary olfactory training
Study NCT02523651 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DPSC injection
Description: A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
Study NCT02523651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
Study NCT04905225 — intervention group
Intervention type: PROCEDURE
Intervention: Ascending aortic replacement
Description: Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
Study NCT00586586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
Study NCT04575285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram (EEG)
Description: EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
Study NCT04710225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting
Description: Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure.
Study NCT02975037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil 25 mg PO
Study NCT02975037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: clarithromycin 250 mg PO
Study NCT02975037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: itraconazole 100 mg PO
Study NCT01570816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRS-8 (8 channel implanted receiver stimulator)
Description: Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
Study NCT02269644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: dalbavancin 1500 mg IV over 30 minutes on Day 1
Study NCT02269644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
Study NCT02269644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Linezolid Placebo
Description: Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
Study NCT02269644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
Study NCT02165306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure
Study NCT02165306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine counseling
Description: All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
Study NCT04250831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: agglomerated glucomannan, oligofructose and chromium mixture
Description: Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
Study NCT00845325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group One
Description: They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
Study NCT00845325 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group Two
Description: The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
Study NCT03282006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pivmecillinam
Description: Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
Study NCT02976259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
Study NCT02610764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test for CTC evaluation
Study NCT04109313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
Study NCT03188094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW-Led Health Coaching
Description: The CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to prevent diabetes.
Study NCT03188094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR Alerts
Description: Primary care providers (PCP) treating patients in the intervention group will receive embedded EHR alerts to increase screening and identification of South Asian patients at-risk for T2DM with BMI >23 kg/m2 and registries to track outcomes.
Study NCT01924780 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NEMOS Device sham stimulation 10 minutes
Study NCT01416025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospective TDM Arm
Description: Voriconazole dose will be adjusted based on per protocol obtained TDM levels
Study NCT02236676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nap after rehearsal trials
Description: Behavioral
Study NCT02236676 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nap after rehearsal trials
Description: Behavioral
Study NCT02950337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 1: Peripherally Located Tumors
Description: Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
Study NCT02950337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 2: Peripherally Located Chest Wall Adjacent Tumors
Description: Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
Study NCT02950337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 3: Centrally Located Tumors
Description: Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
Study NCT03755193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of SERM and ELD in osteoporosis patients